FDA OKs Vivus Weight Drug Qsymia After Nod To Rival Arena

Law360, New York (July 17, 2012, 10:17 PM EDT) -- The U.S. Food and Drug Administration on Tuesday approved Mountain View, Calif.-based drugmaker Vivus Inc.’s weight-loss drug Qsymia, weeks after approving rival Arena Pharmaceuticals Inc.’s weight-loss treatment Belviq.

The FDA approved Qsymia, a combination of weight-loss drug phentermine and seizure and migraine drug topiramate, as a weight-loss supplement that like Belviq, or lorcaserin hydrochloride, can be taken by obese adults as well overweight patients with other weight-related health problems including high blood pressure, type 2 diabetes and high cholesterol.

The approvals follow years of stigma against...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.